SCHEMBL2856828

SCHEMBL2856828

CNC(=O)c1ccc(-c2cccc(Nc3cc(C)ccn3)n2)s1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 10/20 0.54
SYK P43405 1/20 0.49
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
JAK2 O60674 2/20 0.44
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
KCNH2 Q12809 1/20 0.42
LCK P06239 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13136552 0.89 KARS1 (0.56) KARS1SYKNPC1RAB9AMEN1
SCHEMBL2864883 0.89 KARS1 (0.56) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136588 0.88 KARS1 (0.51) KARS1SYKNPC1RAB9AMEN1
SCHEMBL2869562 0.88 KARS1 (0.55) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136551 0.87 KARS1 (0.54) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136647 0.86 SYK (0.51) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136555 0.86 KARS1 (0.58) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136634 0.86 KARS1 (0.49) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136554 0.86 KARS1 (0.53) KARS1SYKNPC1RAB9AMEN1
SCHEMBL13136576 0.86 KARS1 (0.53) KARS1SYKNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP claimed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US claimed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity SYK, BTK, ZAP70 KARS1 2175/4885SYK 1/4885NPC1 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.